Table 1.

Association of clinicopathologic features with time to biochemical failure using univariate Cox regression models

Variable	N	%	HR (95%CI)	P-value
Total population	96
Gleason score				0.937
3+4	63	41.2	0.96 (0.32–2.88)
4+3	33	21.6	1.00
Pathologic stage				0.036
Extraprostatic extension (pT3+)	22	22.9	3.26 (1.08–9.80)
Prostate-limited (pT2)	74	77.1	1.00
Lymph node involvement				0.116
Yes (pN1)	3	3.1	3.52 (0.74–16.81)
No (pN0)	93	96.9	1.00
Surgical margin involvement				0.016
Yes (pR1)	40	41.7	4.86 (1.35–17.54)
No (pR0)	56	58.3	1.00
Non-Localized Tumor Indicator*				0.022
Yes	50	52.1	5.75 (1.28–25.74)
No	46	47.9	1.00
	N	Mean (SD)	HR (95%CI)	P-value
Age (years)	90	61.1 (6.6)	1.05 (0.97–1.14)	0.257
Pre-operative PSA (ng/mL)	96	7.4 (5.2)	1.06 (1.00–1.13)	0.070

^*Non-Localized Tumor Indicator is a summary metric of tumor confined to prostate. ‘Yes’ indicates extraprostatic extension (pathologic stage pT3+), involved lymph nodes (pN1), and/or positive surgical margins (pR1).